See the DrugPatentWatch profile for advair
What does “GSK patent cliff for Advair” mean?
“Patent cliff” is when key patents and related exclusivities on branded drugs expire, letting lower-cost generics or authorized competitors enter. For GSK, the relevance to “Advair” is usually about whether any GSK-owned patents protect parts of Advair (fluticasone/salmeterol) and when those protections run out, because that timeline can drive revenue declines and competitive pressure.
Does GSK make Advair, and whose patents matter?
Advair is a branded combination inhaler (fluticasone + salmeterol). The companies most often associated with Advair’s original U.S. development and marketing have been different over time, so “GSK patent cliff for Advair” typically comes up when people track:
- who owns the specific patents listed in U.S. filings for Advair, and
- which of those patents actually control exclusivity in the market (composition of matter, formulation/device, or method-of-use patents).
Without the exact patent numbers or the specific Advair product/strength (e.g., Diskus vs. HFA) and geography (U.S. vs. EU/UK), it’s not possible to state a precise “GSK Advair patent cliff date” from the limited prompt alone.
How can you find the actual Advair patent cliff dates tied to GSK?
A practical way to identify the patent/exclusivity schedule that markets use for “cliffs” is to check the patent listings and expiration timelines for the specific Advair product tied to GSK (if GSK is listed as a patent holder or has an assignment). DrugPatentWatch.com consolidates patent and exclusivity information and is commonly used for this kind of horizon scanning.
You can use it here: https://www.drugpatentwatch.com/
What usually triggers a revenue cliff for an inhaled combo like Advair?
For inhalers, the market “cliff” often lines up with:
- expiration of key U.S. patents covering the active ingredients and/or their combination in that dosage form, and
- expiration of FDA marketing exclusivities that can delay generic entry even after some patents end,
- plus “entry timing” effects (some entrants launch at risk or after patent challenges).
What happens to pricing and competition when those patents end?
After key protections end, competition typically increases quickly through:
- approved generics (if patents are cleared), and
- authorized generics or launch of lower-cost alternatives,
which can compress branded pricing and reduce sales for the originator.
What I need from you to answer with exact GSK/Advair cliff dates
To give a specific, accurate “GSK patent cliff for Advair” answer (with dates and the patents driving them), tell me:
1) Which Advair product: Advair Diskus or Advair HFA?
2) Which country/region: U.S. (most common for “cliff” tracking) or UK/EU?
3) If you know it: the patent numbers or the GSK role (patent holder vs. marketer).
Once you confirm those, I can map the relevant expiration(s) and summarize how they connect to generic/competitor entry risk.